| Similar Articles |
|---|
 |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry.   |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
February 16, 2006
Stephen D. Simpson |
Lab Corp Doesn't Pass the Test Lab Corp may be a well-run company, but there just isn't enough room in the stock price. |
The Motley Fool
December 31, 2008
Brian Orelli |
Health Care's Golden Children The whole industry wasn't down this year. |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
April 30, 2009
Brian Orelli |
How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
January 27, 2009
Brian Orelli |
Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times. |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
The Motley Fool
September 30, 2009
Brian Orelli |
Call Me a Wimp, but I'm Still Nervous Can the mud Sequenom seems to be running in turn to quicksand? |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
The Motley Fool
June 13, 2008
Brian Orelli |
China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? |
Chemistry World
August 3, 2009
Rebecca Trager |
Vandalism strikes US lab An apparent case of inside vandalism has caused approximately $500,000 worth of research samples to be destroyed at the SLAC National Accelerator Laboratory in Menlo Park, California, US. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
Bio-IT World
March 2007
Michael A. Greeley |
Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities. |
The Motley Fool
June 10, 2009
Brian Orelli |
Up 58% on No News? What's Going On? There's no concrete reason for the massive increase in Sequenom yesterday. The stock was flat until noon, then it steadily climbed up to the moon in afternoon trading. |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns. |
Bio-IT World
October 10, 2003
Robert M. Frederickson |
Capturing Clinical Information Ardais is building a repository of clinical samples and related patient data. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
The Motley Fool
August 16, 2011
Jeremy Phillips |
Read This Before You Think About Selling Sequenom I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%. |
Chemistry World
August 1, 2012
Patrick Walter |
Phenomenal Olympic science legacy (or is that sustainability?) What do you do with a lab set up solely to catch Olympic drug cheats once the games are over? In the case of the London 2012 games, the answer is to turn it into a state of the art analytical lab. |
Chemistry World
February 11, 2011
Elinor Richards |
Thirty minute flu gene detector Scientists in Japan have developed a portable influenza testing kit with better accuracy than current methods, which can give a result in 30 minutes. |
HHMI Bulletin
Fall 2012
Robert Tjian |
President's Letter: Stabilizing Forces Recognizing the role of research professionals in today's laboratory organizations is important not only to the individuals who contribute their services but also to the research enterprise as a whole. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
National Defense
February 2012
Eric Beidel |
Army Lab Analyzes Bad Dust From War Zones The Army Research Laboratory has deployed equipment to Iraq, Afghanistan and Africa to find out if particles floating around in the air in these places are causing Gulf War Syndrome and other illnesses. |
Chemistry World
October 8, 2012
Rebecca Trager |
US crime lab chemist arrest causes reverberations Last month's arrest of a chemist, who worked in a Massachusetts Department of Public Health state laboratory, for allegedly falsifying evidence used in criminal cases is prompting calls for major forensic science reform in the US. |
Food Engineering
June 1, 2008
Richard F. Stier |
Is it Possible to Control Chemical Hazards in Food? It is imperative buyers establish programs to verify the quality of all purchased lots. |
Pharmaceutical Executive
September 1, 2008 |
Place Your Bets The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
